The CMS has just announced a new list of medicines selected for this program that includes Novo Nordisk's Wegovy, Ozempic, ...

A rebound in Denmark’s pharmaceutical industry, dominated by Novo Nordisk A/S, powered the economy to its fastest quarterly ...

A 2.3% quarterly jump, according to Statistics Denmark, was powered almost entirely by the pharmaceutical engine dominated by ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs ...

Novo Nordisk (NVO) announced 5,000 job cuts in Denmark last September, putting the Nordic nation to record its worst year for job losses since 2020. Read more here.

Dec 2 () - Wegovy maker Novo Nordisk is planning ​to test its experimental obesity drug, ‌CagriSema, in overweight children ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday ...

Weaker prospects for pharmaceutical giant Novo Nordisk A/S (NYSE:NVS) have prompted Denmark's economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage points ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare ...

Novo Nordisk (NYSE: NVO), a Denmark-based drugmaker, is currently a leader in the rapidly growing weight loss market. The ...